Yibo Tang

Dr. Yibo Tang

Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2022 in Cells
Verified
Journal Article
Open access
PDF file
LZLixia Zhang
Lixia Zhang
QWQi Wu
Qi Wu
SZShuqi Zhu
Shuqi Zhu
YTYibo Tang
Yibo Tang
YCYanmin Chen
Yanmin Chen
ZLZhaoxia Liang
Zhaoxia Liang
Gestational diabetes mellitus (GDM) leads to poor pregnancy outcomes and fetoplacental endothelial dysfunction; however, the underlying mechanisms remain unknown. This study aimed to investigate the effect of placenta-derived exosomal miRNAs on fetoplacental endothelial dysfunction in GDM, as well as to further explore the role of chemerin to this end. Placenta-derived exosomal miR-140-3p and miR-574-3p expression (next-generation sequencing, quantitative real-time PCR), its interactions with cell function (Cell Counting Kit-8, Transwell, tube formation assay), chemerin interactions (Western blotting), and placental inflammation (immunofluorescence staining, enzyme-linked immunosorbent assay) were investigated. Placenta-derived exosomal miR-140-3p and miR-574-3p were downregulated in GDM. Additionally, miR-140-3p and miR-574-3p inhibited the proliferation, migration, and tube formation ability of umbilical vein endothelial cells by targeting vascular endothelial growth factor. Interestingly, miR-140-3p and miR-574-3p expression levels were negatively correlated with chemerin, which induced placental inflammation through the recruitment of macrophage cells and release of IL-18 and IL-1β. These findings indicate that chemerin reduces placenta-derived exosomal miR-140-3p and miR-574-3p levels by inducing placental inflammation, thereby promoting the proliferation, migration, and tube formation of umbilical vein endothelial cells in GDM, providing a novel perspective on the underlying pathogenesis and therapeutic targets for GDM and its offspring complications.

1 September 2021 in Reproductive Biology
Verified
Journal Article
Open access
LCLili Cao
Lili Cao
YTYibo Tang
Yibo Tang
XNXiaocen Niu
Xiaocen Niu
QGQingyun Guo
Qingyun Guo
LHLili Huang
Lili Huang
Mifepristone has been used for first-trimester abortion and contraception. Nevertheless, its functional mechanism still needs to be elucidated. Decidua tissues were collected from 40 pregnant women who received (20 patients) or did not receive (20 patients) mifepristone. Immunofluorescence was used to analyze the effect of mifepristone on the quantity of CD56 and CD206 in decidua. in vitro assay, NK cells were isolated from decidua tissue and macrophages were induced from THP-1 cells. NK cells were co-cultured with macrophages pre-treated different concentrations of mifepristone (0 nmol/L, 200 nmol/L, 1800 nmol/L, and 25000 nmol/L); the cells' cytotoxicity and migration ability were analyzed using MTT assay and transwell assay, respectively. Si-TGF-β1, which was utilized to knock down the TGF-β1 expression in macrophages and human recombinant TGF-β1 were used to verify whether TGF-β1 was involved in the mifepristone regulation of NK cells function. The quantity of CD56 and CD206 decreased after mifepristone treatment. Moreover, the NK cells' cytotoxicity and migration ability were significantly increased by macrophages pre-treated with mifepristone in a dose-dependent manner. Moreover, compared with the si-NC group, the MTT absorbance rate of NK cells was significantly increased in the si-TGF-β1 group and was decreased in the human recombinant TGF-β1 group. Our data suggest that mifepristone, which regulates NK cells function through macrophages, was associated with the changes in TGF-β1 secreted by macrophages. This may be one of the mechanisms of mifepristone acting as contraceptive and abortion drugs at the maternal-fetal interface.

5 July 2021 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
XNXiaocen Niu
Xiaocen Niu
YTYibo Tang
Yibo Tang
SLSongyue Li
Songyue Li
SNShanshan Ni
Shanshan Ni
WZWanren Zheng
Wanren Zheng
LHLili Huang
Lili Huang

29 December 2021 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
WZWanren Zheng
Wanren Zheng
YTYibo Tang
Yibo Tang
CWChunfen Wang
Chunfen Wang
XNXiaocen Niu
Xiaocen Niu
ZQZhida Qian
Zhida Qian
LHLili Huang
Lili Huang
This study aimed to estimate the difference in vaginal bleeding pattern, discontinuation rate, and satisfaction between immediate after abortion and menstrual insertions of etonogestrel contraceptive implants. Between May 2013 and November 2015, 66 women were recruited in the abortion group who selected etonogestrel implants as their contraceptive immediately after induced abortion. 84 women who underwent the placement of the etonogestrel implant during their menstrual period were enrolled as the menstrual group. The two groups participated in 3-year follow-up outpatient visits at 1, 6, 12, 24, and 36 months after implantation. The vaginal bleeding pattern, discontinuation rate, satisfaction rate were recorded and compared. No woman had pregnancy over the study period of 3 years. The incidence of amenorrhea/infrequent bleeding did not differ between the two groups after 12, 24, and 36 months of implantation (53.0% vs. 58.4%, 47.8% vs. 51.6%, and 48.6% vs. 55.6%, respectively). In the abortion group, the incidences of frequent/prolonged bleeding were 15.1%, 32.6%, and 27.0% after 12, 24, and 36 months of implantation, respectively, while the other group showed 27.3%, 25.8%, and 20.4%, respectively. After 12 and 24 months, the continuation use rates were 69.7% and 56.1% in the abortion group and 73.8% and 64.2% in the menstrual group. The 12-month satisfaction rate between abortion group and menstrual group was 69.6% versus 72.6%. Statistical analyses show that there was no difference in vaginal bleeding pattern, discontinuation rate or satisfaction between the two groups. Immediately post-abortion may be also a favorable time to undergo etonogestrel implantation.